RAB37 and lung cancer: These clinical data suggest that tumors from lung cancer patients with poor survival rates or poor chemo-responses are characterized by a distinct immunosuppressive TME with a high level of infiltrating Rab37+ST2L+CD206+ tumor-associated M2 macrophages.